2. Ca-
3. ( FIGO )
4. ( FIGO )
5. 5 77% S1 G3 84% S1 G2 91% S1 G1 60% S3 15% S4 75% S2 90% S1 6.
7.
8.
9. 10. RT II 11. RT III RT III ? 12. 13. ()
14.
RT III 15. S-RT S + RT Elliot,1994 15% 2,6% Carey, 1995 15% 4% Cadar, 1992 70% 33% Morrow, 1991 30% 15% 16. RT 17. 18.
RT III 19. 20. 21. 22. T GOG&PORTEC RT RT P ostO perativeR adiationT herapy inE ndometrialC ancer 23. III
Creutzberg, Lancet 355, April, 2000 Keys, Gyn Onc 92, 744-751, 2004 24.
high risk 25. PORTEC (-) 10 RT : 14%vs RT :5% (p200 cGy
34. 2D 3D 35. ASTEC EN.5 STUDY 905 452 51% 453 52% 71% ATH BSO 29% ATH BSOPLN EN.5: July 1996- ASTEC: July 1998- 36. ASTEC EN.5 STUDY GRADE I GRAD II GRADE III O / ASTEC EN.5ASTEC EN.5 ASTEC EN.5 ASTEC EN.5 C ASTEC EN.5ASTEC EN.5ASTEC EN.5ASTEC EN.5 ASTEC EN.5ASTEC EN.5ASTEC EN.5ASTEC 37. ASTEC 5 : 8 5.6% vs8 5.4 % (p=0.98) 38. ASTEC : 82%vs79% (p=0.37) 39. ASTEC EN.5 STUDY 453 452 26% 60% ( 17%) ( 8%) (